(NASDAQ: PVLA) Palvella Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.46%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.74%.
Palvella Therapeutics's earnings in 2026 is -$41,715,000.On average, 18 Wall Street analysts forecast PVLA's earnings for 2026 to be -$75,627,649, with the lowest PVLA earnings forecast at -$91,178,008, and the highest PVLA earnings forecast at -$47,492,721. On average, 17 Wall Street analysts forecast PVLA's earnings for 2027 to be -$89,896,935, with the lowest PVLA earnings forecast at -$156,685,900, and the highest PVLA earnings forecast at -$41,030,104.
In 2028, PVLA is forecast to generate -$46,931,625 in earnings, with the lowest earnings forecast at -$158,228,912 and the highest earnings forecast at $60,868,835.